Application of cytogenetic endpoints and comet assay on human lymphocytes treated with atorvastatin in vitro

References

• Newman , C. B. , Palmer , G. , Silbershatz , H. and Szarek , M. 2003 . Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients . Am. J. Cardiol. , 92 : 670 – 676 .
   PubMed Web of Science ®Google Scholar
• Grundy , S. M. 2005 . The issue of statin safety: where do we stand? . Circulation. , 111 ( 23 ) : 3106 – 3109 .
   Web of Science ®Google Scholar
• Naoumova , R. P. , O'Neill , F. H. , Dunn , S. , Neurwirth , C. K. , Taylor , G. W. , Axelson , M. and Thompson , G. R. 1999 . Effect of inhibiting HMG-Coa reductase on 7α -hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway . Eur. J. Clin. Invest. , 29 : 404 – 412 .
   PubMedGoogle Scholar
• Guerin , M. , Lassel , T. S. , Le-Goff , W. , Farnier , M. and Chapman , M. J. 2000 . Action of atorvastatin in combined hyperlipidemia: preferential reduction of Cholesteryl ester transfer from HDL to VLDL1 particles . Arterioscler. Thromb. Vasc. Biol. , 20 : 189 – 197 .
   PubMed Web of Science ®Google Scholar
• Noseda , G. , Darioli , R. , Keller , U. , Mordasini , R. , Shokry , A. , Schaffhauser , B. and Riesen , W. 2000 . Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study) . Schweiz. Med. Wochenschr. , 130 : 889 – 895 .
   PubMedGoogle Scholar
• Schrott , H. G. , Knapp , H. , Davila , M. , Shurzinske , L. and Black , D . 2000 . Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study . Am. Heart. J. , 140 : 249 – 252 .
   PubMed Web of Science ®Google Scholar
• Tolman , K. G. 2002 . The liver and lovastatin . Am. J. Cardiol. , 89 : 1374 – 1380 .
   PubMed Web of Science ®Google Scholar
• Omar , M. A. and Wilson , J. P. 2002 . FDA adverse event reports on statin-associated rhabdomyolysis . Ann. Pharmachoter. , 36 : 288 – 295 .
   PubMed Web of Science ®Google Scholar
• Grundy , S. M. , Cleeman , J. I. , Merz , C. N. , Brewer , H. B. Jr. , Clark , L. T. , Hunninghake , D. B. , Pasternak , R. C. , Smith , S. C. Jr. , Stone , N. J. and National Heart, Lung, and Blood Institute, American College of Cardiology Foundation; American Heart Association . 2004 . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines . Circulation. , 110 : 227 – 239 .
   PubMed Web of Science ®Google Scholar
• LaRosa , J. C. , Grundy , S. M. , Waters , D. D. , Shear , C. , Barter , P. , Fruchart , J. C. , Gotto , A. M. , Greten , H. , Kastelein , J. J. , Shepherd , J. and Wenger , N. K. 2005 . Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease . N. Engl. J. Med. , 352 : 1425 – 1435 .
   PubMed Web of Science ®Google Scholar
• Harangi , M. , Seres , I. , Varga , Z. , Emri , G. , Szilvássy , Z. , Paragh , G. and Remenyik , É . 2004 . Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage . Eur. J. Clin. Pharmacol. , 60 : 685 – 691 .
   PubMed Web of Science ®Google Scholar
• Ajith , T. A. and Soja , M. 2006 . A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens . Cell. Biol. Toxicol. , 22 : 269 – 274 .
   PubMed Web of Science ®Google Scholar
• Albertini , R. J. , Anderson , D. , Douglas , G. R. , Hagmar , L. , Hemminki , K. , Merlo , F. , Natarajan , A. T. , Norppa , H. , Shuker , D. E.G. , Tice , R. , Waters , M. D. and Aitio , A. 2000 . ICPS guidelines for the monitoring of genotoxic effects of carcinogens in humans . Mutat. Res. , 463 : 111 – 172 .
   PubMed Web of Science ®Google Scholar
• IAEA . 1–69 1986 . Biological dosimetry—chromosomal aberration analysis for dose assessment , 1–69 , Vienna , , Austria : International Atomic Energy Agency . Technical Report Series No. 260,
   Google Scholar
• Latt , S. A. , Allen , J. , Bloom , S. E. , Carrano , A. , Falke , E. , Kram , D. , Schneider , E. , Schreck , R. , Tice , R. , Whitefield , B. and Wolff , S. 1981 . Sister-chromatid exchanges: a report of the gene-tox program . Mutat. Res. , 87 : 17 – 62 .
   PubMed Web of Science ®Google Scholar
• Singh , N. P. , McCoy , M. T. , Tice , R. R. and Schneider , L. L. 1988 . A simple technique for quantitation of low levels of DNA damage in individual cells . Exp. Cell. Res. , 175 : 184 – 191 .
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) . 2002 . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report . Circulation. , 106 : 3143 – 3421 .
   PubMed Web of Science ®Google Scholar
• Pyorala , K. , Pedersen , T. R. , Kjekshus , J. , Faergeman , O. , Olsson , A. G. and Thorgeirsson , G. 1997 . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) . Diabetes. Care. , 20 : 614 – 620 .
   PubMed Web of Science ®Google Scholar
• Goldber , R. B. , Mellies , M. J. , Sacks , F. M. , Moye , L. A. , Howard , B. V. , Howard , W. J. , Davis , B. R. , Cole , T. G. , Pfeffer , M. A. and Braunwald , E. 1998 . Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial: the Care Investigators . Circulation. , 98 : 2513 – 2519 .
   PubMedGoogle Scholar
• Crick , D. C. , Andres , D. A. , Danesi , R. , Macchia , M. and Waechter , C. J. 1998 . Geranyl-geraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells . J. Neurochem. , 70 : 2397 – 2404 .
   PubMed Web of Science ®Google Scholar
• Betti , C. , Davini , T. , Gianessi , L. , Loprieno , N. and Barale , R. 1994 . Microgel electrophoresis assay (comet test) and SCE analysis in human lymphocytes from 100 normal subjects . Mutat. Res. , 307 : 323 – 333 .
   PubMed Web of Science ®Google Scholar
• Fairbairn , D. W. , Olive , P. L. and O'Neill , K. L. 1995 . The comet assay: a comprehensive review . Mutat. Res. , 339 : 37 – 59 .
   PubMed Web of Science ®Google Scholar
• Collins , A. , Dusinska , M. , Franklin , M. , Somorovska , M. , Petrovska , H. , Duthie , S. , Fillion , L. , Panayiotidis , M. , Raslova , K. and Vaughan , N. 1997 . Comet assay in human biomonitoring studies – reliability, validation, and applications . Environ. Mol. Mutagen. , 30 ( 2 ) : 139 – 146 .
   PubMed Web of Science ®Google Scholar
• Wojewódzka , M. , Kruszewski , M. , Iwanenko , T. , Collins , A. R. and Szumiel , I. 1998 . Application of the comet assay for monitoring DNA damage in workers exposed to chronic low-dose irradiation . I. Strand breakage. Mutat. Res. , 416 : 21 – 35 .
   PubMed Web of Science ®Google Scholar
• Olive , P. L. 1999 . DNA damage and repair in individual cells: aplications of the comet assay in radiobiology . Int. J. Rad. Biol. , 75 ( 4 ) : 395 – 405 .
   PubMed Web of Science ®Google Scholar
• Kopjar , N. and Garaj-Vrhovac , V . 2001 . Application of the alkaline comet assay in human biomonitoring for genotoxicity: a study on Croatian medical personnel handling antineoplastic drugs . Mutagenesis. , 16 ( 1 ) : 71 – 78 .
   PubMed Web of Science ®Google Scholar
• Hartman , A. , Plappert , U. , Poetter , F. and Suter , W. 2003 . Comparative study with the alkaline comet assay and the chromosome aberration test . Mutat. Res. , 536 : 27 – 38 .
   PubMed Web of Science ®Google Scholar
• Ciaravino , V. , Kropko , M. L. , Rothwell , C. E. , Hovey , C. A. and Theiss , J. C. 1999 . The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia . Mutat. Res. , 343 ( 2–3 ) : 95 – 107 .
   Web of Science ®Google Scholar
• Raslova , K. , Dobiasova , M. , Nagyova , A. , Fabry , R. , Rauchova , H. and Dusinska , M. 1998 . Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage . Eur. J. Clin. Pharmacol. , 54 : 697 – 699 .
   PubMed Web of Science ®Google Scholar
• Wierzbicki , A. S. , Lumb , P. J. , Chik , G. and Crook , M. A. 1999 . Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with hypercholesterolemia . Int. J. Clin. Pract. , 53 : 609 – 611 .
   PubMed Web of Science ®Google Scholar